GSK’s B-Well 2 Hepatitis B Trial Reaches Completion, Setting the Stage for Key Data

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.

The Phase 3 B-Well 2 trial from GlaxoSmithKline tests bepirovirsen in people with chronic hepatitis B who already take standard antiviral pills. The study aims to confirm how well the drug lowers virus surface proteins, how safe it is, and how long the effect lasts, which matters for a large, long-term global market.

The treatment is bepirovirsen, an injected drug designed to reduce hepatitis B virus activity in the body. It is compared with a placebo on top of ongoing standard nucleos(t)ide analogue therapy, with the goal of moving patients closer to a functional cure rather than lifelong maintenance.

The study is interventional and randomized, meaning participants are assigned by chance to drug or placebo. It uses a parallel group design with both patients and researchers blinded, and the main purpose is to test treatment benefit compared with placebo under usual care.

The trial runs in several stages over about two years per participant, moving from double-blind dosing to follow-up off background therapy. The study is listed as completed, and the record was most recently updated on 13 May 2026, signaling that data collection is finished and formal readouts could follow.

For investors, the update reinforces that GSK is pushing a late-stage asset in hepatitis B, a market where curative approaches are still open for disruption. Clear positive data could support sentiment on GSK’s pipeline versus peers working on similar HBV strategies, while any safety or efficacy issues could dampen enthusiasm for this segment.

The study record confirms that the B-Well 2 trial of bepirovirsen in chronic hepatitis B has completed follow-up and has been recently updated, with more details available on the ClinicalTrials portal.

To learn more about GSK’s potential, visit the GlaxoSmithKline drug pipeline page.